ATE442157T1 - Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten - Google Patents

Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE442157T1
ATE442157T1 AT00977328T AT00977328T ATE442157T1 AT E442157 T1 ATE442157 T1 AT E442157T1 AT 00977328 T AT00977328 T AT 00977328T AT 00977328 T AT00977328 T AT 00977328T AT E442157 T1 ATE442157 T1 AT E442157T1
Authority
AT
Austria
Prior art keywords
treatment
monoclonal antibodies
autoimmune diseases
inhibiting
immune response
Prior art date
Application number
AT00977328T
Other languages
English (en)
Inventor
Xiao He
Bruce Hall
Suzanne Hodgkinson
Original Assignee
Bruce Hall
Suzanne Hodgkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bruce Hall, Suzanne Hodgkinson filed Critical Bruce Hall
Application granted granted Critical
Publication of ATE442157T1 publication Critical patent/ATE442157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT00977328T 1999-11-26 2000-11-24 Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten ATE442157T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4312A AUPQ431299A0 (en) 1999-11-26 1999-11-26 Method of inducing immune tolerance
PCT/AU2000/001441 WO2001037860A1 (en) 1999-11-26 2000-11-24 Method of inducing immune tolerance

Publications (1)

Publication Number Publication Date
ATE442157T1 true ATE442157T1 (de) 2009-09-15

Family

ID=3818454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977328T ATE442157T1 (de) 1999-11-26 2000-11-24 Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten

Country Status (7)

Country Link
US (1) US7744863B1 (de)
EP (1) EP1379270B1 (de)
AT (1) ATE442157T1 (de)
AU (2) AUPQ431299A0 (de)
CA (1) CA2429394A1 (de)
DE (1) DE60042941D1 (de)
WO (1) WO2001037860A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP2397189B1 (de) * 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Verfahren zur Modulierung von Immunität
SI1755674T1 (sl) 2004-05-14 2015-04-30 Alexion Pharmaceuticals, Inc. Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa
EP1851308B1 (de) 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Gegen ein spezifisches antigen aktivierte cd4+ cd25+ t-zellen
MX2008011054A (es) 2006-03-02 2009-03-03 Alexion Pharma Inc Prolongacion de supervivencia de un aloinjerto, mediante la inhibicion de actividad de complemento.
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
WO2008063849A2 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
BR112012027531A2 (pt) * 2010-04-29 2017-08-08 Hadasit Medical Res Service And Development Co Ltd método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2015023972A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
BR112022025381A2 (pt) 2020-06-11 2023-01-24 Provention Bio Inc Métodos e composições para prevenir diabetes tipo 1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU7467898A (en) * 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy

Also Published As

Publication number Publication date
EP1379270A4 (de) 2004-01-14
US7744863B1 (en) 2010-06-29
EP1379270B1 (de) 2009-09-09
AUPQ431299A0 (en) 1999-12-23
EP1379270A1 (de) 2004-01-14
CA2429394A1 (en) 2001-05-31
WO2001037860A1 (en) 2001-05-31
DE60042941D1 (de) 2009-10-22
AU1506501A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
ATE177011T1 (de) Cdw52-spezifischer antikörper zur behandlung von multipler sklerose
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DK0724456T3 (da) CD40-Antistoffer
ATE506076T1 (de) Medizinische verwendung von anti-cs1 antikörpern
CY1113489T1 (el) Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0552296T3 (da) Monoklonale antistoffer fra mus
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
HK1044159A1 (zh) 抗γ-干擾素的人化抗體
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
NO981454D0 (no) Anti-FAS-antistoffer
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
TH131300B (th) ตัวแปรอิมมูโนกลูบูลินและการใช้สิ่งนั้น

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties